Skip to content
Bora Haber
Markets
  • US dollar50.44up 0.05%
  • Euro55.34down 0.18%
  • British pound66.55down 0.11%
  • BIST 10011,477down 3.08%
  • Gold (gram)6,041down 3.55%
  • Gold (ounce)US$3,725down 3.6%
  • BitcoinUS$62,686down 1.61%
BREAKING

National and European patents for domestic cancer drug candidate molecules

Academics from Zonguldak Bülent Ecevit and Istanbul Medipol universities developed new drug candidate molecules effective on breast, prostate and lung cancer cells. The invention is protected by two patents.

Nehir Gökçe

· 2 min read

Person in blue lab coat and gloves at a bench with blue, orange, green and red liquids in glass flasks and tubes.
Illustrative image: laboratory glassware used in drug development research. Temsili görsel · Fotoğraf: https://kaboompics.com/ / Pexels

Researchers from Zonguldak Bülent Ecevit University and Istanbul Medipol University developed new drug candidate molecules that could be used in cancer treatment. The study, titled "Synthesis and Investigation of Biological Activities of New Tyrosine Kinase Inhibitors", was carried out by Prof. Dr. Zuhal Gerçek of the Chemistry Department at Zonguldak Bülent Ecevit University's Faculty of Science, Prof. Dr. Mustafa Güzel of Istanbul Medipol University's Faculty of Pharmacy, and researcher Betül Yeşil.

The biological effects of the synthesized molecules on breast, prostate and lung cancer cells were tested in the laboratory. Their effects on different cancer cells were also examined through computer-aided analyses.

A two-stage project

Speaking to reporters, Prof. Dr. Gerçek said the aim of the study was to synthesize molecules that are candidates for cancer drugs and to prove their anticancer activity. She said the project was supported by Scientific Research Projects and consisted of two parts. Explaining that she completed the synthesis of the molecules herself, Gerçek said the second part, the investigation of their anticancer activities, was carried out by Prof. Dr. Mustafa Güzel and Betül Yeşil.

Yaptığımız çalışmalar neticesinde bu yeni moleküllerin özellikle meme, prostat ve akciğer kanseri hücreleri üzerinde etkili olduğunu kanıtlamış olduk. Bu özelliklerini gerek deneysel gerekse teorik olarak ortaya koyduk. Neticesinde bir ulusal, bir de Avrupa patenti olmak üzere iki patentle de bu fikrimizi koruma altına aldık. Böylece yerli ve milli ilaç üretiminde ufak bir adım atmış olduk.

Prof. Dr. Zuhal Gerçek

Background

The invention was registered by the Turkish Patent and Trademark Office in 2024. Its European patent application was also found suitable for registration. The work is thus protected at both the national and European levels.

The new drug candidates are based on a group of molecules known as tyrosine kinase inhibitors. The researchers demonstrated the molecules' effects through both experimental and theoretical methods. These results are seen as a first step for domestic drug development efforts.

Science guides

Take a quiz, vote in a poll

Video news

Comments

Sign in to comment.

More on this topic

See all